Bio Pharma Dive

JULY 16, 2024

The well-funded startup says drugs AbbVie abandoned last year could form a combination regimen with “superior efficacy” to Vertex’s market-leading medicines.

Drugs 284

Drugs Medicine Marketing 284

World of DTC Marketing

JULY 21, 2021

SUMMARY: DTC marketing is not the reason why prescription drugs cost so much. The voices in Washington DC are once again calling for a moratorium on DTC marketing but lawmakers need to understand what DTC marketing actually does as upped to what people believe it does. DTC ads raise awareness around health conditions.

Marketing 285

Marketing Doctors Doctor Drugs 285

Bio Pharma Dive

MAY 3, 2024

The company said data for its Wegovy competitor was promising enough to move the drug into late-stage testing, triggering a stock jump that added billions to Amgen’s market value.

Drugs 289

Drugs Marketing 289

Pharmaceutical Technology

OCTOBER 25, 2023

Experts discuss the key trends in quality improvements and API reshoring for the generic drugs market at CpHI Europe.

Generic Drugs 147

Generic Drugs Marketing Drugs 147

Pharmaceutical Technology

JANUARY 23, 2023

As such, the SLE and LN marketplace is dominated by generics, and GSK’s Benlysta and AstraZeneca’s Saphnelo are the only drugs that have gained marketing approval specifically for SLE in more than 50 years. In previous years, Benlysta has managed to grow the lupus market in terms of value, having generated approximately $492.9m

Marketing 278

Marketing Production Drugs Trials 278

Fierce Pharma

APRIL 4, 2024

Amylyx Pharmaceuticals is keeping a promise by pulling the amyotrophic lateral sclerosis (ALS) therapy Relyvrio off the market after the drug failed in a confirmatory trial. Amylyx is keeping a promise by pulling the amyotrophic lateral sclerosis (ALS) therapy Relyvrio off the market after the drug failed in a confirmatory trial.

Marketing 117

Marketing Drugs Trials 117

Pharmaceutical Technology

DECEMBER 5, 2023

Professor Timothy Mackey talks about the recent reports of fraudulent Ozempic pens and the challenges in chasing drug counterfeiters.

Drugs 278

Drugs Marketing 278

Fierce Pharma

APRIL 23, 2024

The orphan drug sector has long been clearing growth in the larger pharmaceutical market with booming sales. | The orphan drug sector has long been clearing growth in the larger pharmaceutical market with booming sales.

Marketing 114

Marketing Sales Drugs 114

Pharmaceutical Technology

AUGUST 12, 2024

As antibody drug conjugate (ADC)-centred deals dominate the oncology space, biotechs are using newer targets and linkers to differentiate themselves.

Pharma Companies 264

Pharma Companies Antibody Marketing Drugs 264

Bio Pharma Dive

JULY 22, 2024

Private biotech company acquisitions are on their fastest pace in years, a trend some in the industry say is driven by the abundance of mature, but not yet public, drug startups.

Marketing 255

Marketing Drugs 255

World of DTC Marketing

APRIL 20, 2022

We just finished talking to over 200 hundred HCPs about pharma marketing and salespeople to measure any differences since before the pandemic. This was especially true with new drugs that have a significant competitive market. Will they transform their HCP marketing or stick to dated models?

Marketing 218

Marketing Drug Trials Drugs Sales 218

Pharmaceutical Technology

SEPTEMBER 1, 2023

Novo Nordisk's obesity drugs are driving Danish growth as well as record profits as the company becomes second-most valuable in Europe.

Drugs 264

Drugs Marketing 264

Bio Pharma Dive

JULY 10, 2024

Having recently withdrawn its only product from the market, Amylyx hopes to rebound with a drug that regulates GLP-1 activity and is poised to enter pivotal testing early next year.

Drugs 201

Drugs Regulation Production Marketing 201

Bio Pharma Dive

JULY 9, 2024

On Tuesday, regulators updated the public on their yearslong probe of PBM's business practices. The report faults PBMs for profiting at the expense of patients and independent pharmacists.

Marketing 144

Marketing Regulation Drugs 144

Pharmaceutical Technology

JUNE 12, 2023

Lotus Pharmaceuticals and Teraju Pharma have entered a strategic partnership to market Lotus’s products in a range of therapeutic areas in Malaysia. Teraju Pharma will be responsible for marketing and promoting the products using its relationships and infrastructure.

Marketing 242

Marketing Production Branding Manufacturing 242

Pharmaceutical Technology

NOVEMBER 14, 2022

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Oncopeptides’ Pepaxti (melphalan flufenamide; melflufen) along with dexamethasone to treat multiple myeloma patients. Currently, the company is analysing Pepaxti’s market access options in the country.

Marketing 130

Marketing Drugs Clinical Trials Clinical Trials 130

pharmaphorum

APRIL 4, 2024

Amylyx confirmed today that it will withdraw its amyotrophic lateral sclerosis (ALS) therapy Relyvrio/Albrioza from the market in the US and Canada, shortly after the drug failed a clinical trial.

Marketing 98

Marketing Drugs Doctors Doctor 98

Bio Pharma Dive

NOVEMBER 27, 2023

drugmaker withdrew the multiple myeloma drug from the U.S. market because of negative data, new study results might crack open the door to a relaunch. One year after the U.K.

Drugs 284

Drugs Trials Marketing 284

World of DTC Marketing

JANUARY 12, 2022

The word influencer was added to the Merriam-Webster dictionary in 2019, but influencer marketing is nothing new. Scandals, fake followers, bot technologies, and the pandemic crisis converged have put a halt to influencer marketing growth and tarnished the public view of influencers as a whole. bil­lion in 2021.

Marketing 192

Marketing Branding Production Drugs 192

Bio Pharma Dive

OCTOBER 6, 2022

The pharma will invest in the biotech and co-promote its drug teplizumab if the FDA OKs the medicine as a first-of-its-kind diabetes treatment.

Drugs 283

Drugs Marketing Medicine 283

Pharmaceutical Technology

FEBRUARY 23, 2024

The FDA Office of Generic Drugs reported a rise in generic drug approvals, as several first-time generics entered the market.

Generic Drugs 263

Generic Drugs Drugs Marketing 263

Pharmaceutical Technology

APRIL 5, 2024

Last month, Amylyx announced that the Phase III confirmatory trial of ALS drug Relyvrio failed to meet its primary and secondary endpoints.

Drugs 130

Drugs Marketing Trials 130

Drug Discovery World

FEBRUARY 26, 2024

The global ADME toxicology testing market is predicted to generate a revenue of $19.21 Factors such as an increased need to check late-stage drug failures with the adoption of more appropriate toxicity testing methods by pharmaceutical companies are expected to aid revenue generation for the market.

Marketing 59

Marketing Drugs Development 59

pharmaphorum

JUNE 27, 2024

Verona Pharma has claimed FDA approval for its chronic obstructive pulmonary disease (COPD) drug ensifentrine, which has been tipped as a future blockbuster.The first-in-class dual phosphodiesterase (PDE) 3/4 inhibitor – now given the somewhat tongue-twisting brand name of Ohtuvayre – is the first inhaled product with a novel mechanism of action available (..)

FDA Approval 112

FDA Approval Marketing Drugs Branding 112

Pharmaceutical Technology

MARCH 27, 2024

The market for multiple sclerosis therapies is expected to be worth over $41bn by 2030, according to GlobalData.

Marketing 130

Marketing Licensing Licensing Drugs 130

BioSpace

MAY 14, 2024

Crackdowns on drug pricing have forced one major insulin out of the market. Are more to come?

Insulin 94

Insulin Marketing Sales Drugs 94

Fierce Pharma

SEPTEMBER 7, 2023

Demand is so strong for Novo Nordisk’s obesity drugs that the only limitation on sales—in the short term—seems to be the company’s ability to produce them. Morgan, which has doubled its market projection for GLP-1 diabetes and obesity treatments to $71 billion for 2032.

Marketing 136

Marketing Drugs Sales 136

Fierce Pharma

MARCH 8, 2024

After reporting the failu | After reporting the failure of a confirmatory trial of its amyotrophic lateral sclerosis drug Relyvrio (AMX0035), Amylyx Pharmaceuticals is uncertain whether it will pull the treatment from the market in the U.S. and in Canada, where it is known as Albrioza.

Marketing 98

Marketing Trials Drugs 98

Drug Patent Watch

OCTOBER 2, 2023

The FDA conducted a study to identify factors that may predict the likelihood of generic drug marketing applications.

Generic Drugs 111

Generic Drugs Marketing Drugs 111

Roots Analysis

AUGUST 1, 2024

GLP-1 receptor agonist market have captured the attention of both large and small pharmaceutical companies, for more than a decade. However, after a decade-long dribble of GLP-1 drugs and the recent approval of obesity drugs, the domain has gained significant attention.

Marketing 52

Marketing Insulin Drugs Development 52

BioSpace

APRIL 3, 2024

Following disappointing late-stage data, Amylyx on Thursday said it is withdrawing the company’s amyotrophic lateral sclerosis drug Relyvrio from the U.S. and Canadian markets and cutting its workforce by approximately 70%.

Marketing 93

Marketing Drugs 93

pharmaphorum

MAY 21, 2024

Going against the advice of the CHMP, the EU has said that PTC Therapeutics’ Translarna therapy for Duchenne muscular dystrophy should stay on the market

Marketing 105

Marketing Drugs 105

pharmaphorum

JULY 19, 2024

Less than two years after pulling multiple myeloma therapy Blenrep off most markets around the world, GSK has filed for approval of the drug in the EU once again, hoping to restore its blockbuster credentials.The remarkable renaissance for the BCMA-directed antibody-drug conjugate is supported by a pair of phase 3 trials that could not only support (..)

Marketing 103

Marketing Antibody Trials Drugs 103

pharmaphorum

JUNE 5, 2024

KRAS inhibitors from Eli Lilly, Genfleet, and InxMed make their case for use in NSCLC at ASCO, as they case down Amgen and Bristol-Myers Squibb's market drugs

Marketing 115

Marketing Drugs 115

Drug Discovery World

JUNE 1, 2023

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. A Nature publication confirmed that there are currently 12 FDA-approved ADCs on the market, and nine of these secured FDA approval in the past six years 2.

Antibody 98

Antibody Marketing Drugs Licensing 98

XTalks

OCTOBER 4, 2023

Health economics and outcomes research (HEOR) and market access strategies play a critical role in ensuring that newly approved therapies are made available to patients. Professionals in these roles are facing new challenges when it comes to negotiating coverage for many of the new, innovative treatments that are coming to market.

Marketing 105

Marketing Development Drugs Gene Therapy 105

Outsourcing Pharma

SEPTEMBER 29, 2023

Chinese biopharmaceutical company, Hutchmed Limited, has announced today (Friday September 29) that it has taken a step towards bringing a colon and rectum cancer drug to a third market.

Marketing 86

Marketing Drugs Clinical Development Development 86